HUTCHMED (China) Limited (HCM) RNS Announcements

Add to Alert list
Date Time Source Announcement
15 Apr 2019 07:00 AM
RNS
HK Listing Application - Proposed Global Offering
29 Mar 2019 07:00 AM
RNS
Start of Phase IIb/III Surufatinib Trial in China
28 Mar 2019 07:30 AM
RNS
Savolitinib Lung Cancer Presentations at AACR
25 Mar 2019 07:00 AM
RNS
Vesting of awards under Long Term Incentive Plan
21 Mar 2019 07:00 AM
RNS
Chi-Med 2018 Annual Report and Notice of AGM
11 Mar 2019 12:54 PM
RNS
Publication of Form 20-F
11 Mar 2019 07:00 AM
RNS
2018 FY Results and Key Clinical Programs Update
12 Feb 2019 07:00 AM
RNS
Savolitinib PRCC Data to be presented at ASCO GU
08 Feb 2019 07:00 AM
RNS
Chi-Med to Announce 2018 Final Results
07 Jan 2019 07:00 AM
RNS
Chi-Med Presents at JPM Healthcare Conference
31 Dec 2018 07:00 AM
RNS
Blocklisting Six Monthly Return
31 Dec 2018 07:00 AM
RNS
Total Voting Rights
24 Dec 2018 12:41 PM
RNS
Second Price Monitoring Extn
24 Dec 2018 12:36 PM
RNS
Price Monitoring Extension
20 Dec 2018 07:13 AM
RNS
Chi-Med announce Savolitinib program update
20 Dec 2018 07:00 AM
RNS
Amendment to Lilly Agreement on Fruquintinib
14 Dec 2018 07:21 AM
RNS
TR-1: Form for notification of major holdings
30 Nov 2018 07:00 AM
RNS
Total Voting Rights
29 Nov 2018 08:00 AM
RNS
Chi-Med Enters into Multiple Collaborations
26 Nov 2018 07:00 AM
RNS
First Commercial Launch of Fruquintinib Capsules
16 Nov 2018 07:00 AM
RNS
Phase III FALUCA Trial Results for Fruquintinib
31 Oct 2018 07:00 AM
RNS
Total Voting Rights
22 Oct 2018 10:05 AM
RNS
Grant of Share Options under Share Option Scheme
18 Oct 2018 07:00 AM
RNS
Chi-Med Initiates a Ph I Trial of HMPL-523 for AML
05 Oct 2018 07:00 AM
RNS
Appointment of HSBC Bank plc as Broker in London
05 Sep 2018 07:00 AM
RNS
Fruquintinib Approved for CRC in China
31 Aug 2018 07:00 AM
RNS
Total Voting Rights
07 Aug 2018 10:00 AM
RNS
Grant of Share Options under Share Option Scheme
27 Jul 2018 07:00 AM
RNS
2018 Interim Results and Clinical Programs Update
23 Jul 2018 07:00 AM
RNS
Start of Sulfatinib US Phase Ib/II PoC trial
29 Jun 2018 07:02 AM
RNS
Total Voting Rights
29 Jun 2018 07:01 AM
RNS
Blocklisting Six Monthly Return
29 Jun 2018 07:00 AM
RNS
Chi-Med to Announce Half-Year Financial Results
07 Jun 2018 10:00 AM
RNS
Grant of Share Options under Share Option Scheme
04 Jun 2018 09:41 AM
RNS
Further Fruquintinib FRESCO Trial Data - ASCO 2018
31 May 2018 07:00 AM
RNS
Total Voting Rights
30 Apr 2018 07:00 AM
RNS
Total Voting Rights
27 Apr 2018 01:52 PM
RNS
Results of Annual General Meeting
23 Apr 2018 01:10 PM
RNS
Grant of Share Options under Share Option Scheme
23 Apr 2018 01:05 PM
RNS
Block Admission
29 Mar 2018 07:00 AM
RNS
Total Voting Rights
28 Mar 2018 07:00 AM
RNS
Vesting of awards under Long Term Incentive Plan
26 Mar 2018 07:00 AM
RNS
Annual Report & Notice of Annual General Meeting
21 Mar 2018 09:25 AM
RNS
Director's Share Dealing
20 Mar 2018 09:15 AM
RNS
Grant of Share Options under Share Option Scheme
19 Mar 2018 07:10 AM
RNS
Director's Share Dealing
12 Mar 2018 11:22 AM
RNS
Publication of Form 20-F
12 Mar 2018 07:02 AM
RNS
Final Results and Key Clinical Programs Update
06 Mar 2018 07:00 AM
RNS
Phase Ib/II Trial of Epitinib in Glioblastoma
13 Feb 2018 07:01 AM
RNS
Enrolment completed Ph III FALUCA Fruquintinib

Hutchmed China  Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) is headquartered in Hong Kong and markets its products worldwide.

It was founded in 2000 and listed in London in 2018 under the ticker HCM. 

UK 100